C57BL/6NCya-Orai1em1/Cya
Common Name
Orai1-KO
Product ID
S-KO-00687
Backgroud
C57BL/6NCya
Strain ID
KOCMP-109305-Orai1-B6N-VA
When using this mouse strain in a publication, please cite “Orai1-KO Mouse (Catalog S-KO-00687) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Orai1-KO
Strain ID
KOCMP-109305-Orai1-B6N-VA
Gene Name
Product ID
S-KO-00687
Gene Alias
D730049H07Rik, Tmem142a, orai-1
Background
C57BL/6NCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 5
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000121652
NCBI RefSeq
NM_175423
Target Region
Exon 2
Size of Effective Region
~0.6 kb
Overview of Gene Research
Orai1 is a key component of the store-operated Ca2+ release activated Ca2+ (CRAC) channel. It resides in the plasma membrane and, together with STIM1 in the endoplasmic reticulum-membrane, forms a highly Ca2+ selective ion channel complex. This complex is crucial for Ca2+ entry into non-excitable cells, which initiates diverse signalling cascades affecting processes like gene regulation, cell growth and death, secretion, and gene transcription [1].
In animal models of acute kidney injury (AKI), Orai1 is upregulated on lymphocytes. Inhibition of this channel attenuates both acute and chronic kidney injury in rodent models, suggesting it may be a new therapeutic target for the AKI-to-chronic kidney disease (CKD) transition. Also, in a rat model of ischemia/reperfusion, peripheral blood cells show an early and sustained increase in Orai1 expression, indicating that blood cell Orai1 may inform potential Th17 activity in AKI or the AKI-to-CKD transition [2]. In breast cancer cells, the interplay between Orai1 and adenylyl cyclase 8 (AC8) is important. AC8 overexpression in breast cancer cells impairs PKA-dependent Orai1α inactivation, contributing to enhanced store-operated Ca2+ entry (SOCE) [3]. In combined immunodeficiency, ORAI1 gene variations lead to clinical manifestations such as early-onset recurrent infection, congenital hypotonia, and abnormal immune cell counts. Most patients have a poor prognosis [4].
In conclusion, Orai1 is essential for Ca2+-dependent signalling pathways. Model-based research, especially in rodent models, has revealed its role in diseases like AKI-CKD transition, breast cancer, and combined immunodeficiency. Understanding Orai1's function provides potential therapeutic targets for these disease areas.
References:
1. Lunz, Victoria, Romanin, Christoph, Frischauf, Irene. 2018. STIM1 activation of Orai1. In Cell calcium, 77, 29-38. doi:10.1016/j.ceca.2018.11.009. https://pubmed.ncbi.nlm.nih.gov/30530091/
2. Basile, David P, Collett, Jason A. 2021. Orai1: A New Therapeutic Target for the Acute Kidney Injury-to-Chronic Kidney Disease Transition. In Nephron, 146, 264-267. doi:10.1159/000518177. https://pubmed.ncbi.nlm.nih.gov/34515158/
3. Sánchez-Collado, José, López, José J, Rosado, Juan A. 2021. The Orai1-AC8 Interplay: How Breast Cancer Cells Escape from Orai1 Channel Inactivation. In Cells, 10, . doi:10.3390/cells10061308. https://pubmed.ncbi.nlm.nih.gov/34070268/
4. Yang, H Y, Deng, X L, Yin, F, Peng, J, Wu, L W. . [ORAI1 variation induced combined immunodeficiency: a case report and literature review]. In Zhonghua er ke za zhi = Chinese journal of pediatrics, 57, 142-145. doi:10.3760/cma.j.issn.0578-1310.2019.02.015. https://pubmed.ncbi.nlm.nih.gov/30695890/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
